Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06111846 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Human Bone Marrow Mesenchymal Stem Cells in APAP

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 24, 2025 (before its estimated July 22, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 22, 2024 to Jul 22, 2025
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Nov 1, 2023 to Dec 25, 2023
    v3
  2. Secondary endpoints revised (14)v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.
Trial Details
NCT Number NCT06111846
Lead Sponsor Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
Collaborators: The First Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Autoimmune Pulmonary Alveolar Proteinosis
Related terms Pulmonary Alveolar Proteinosis, Acquired
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov